Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population

Background Albeit several studies pointed out the pivotal role that CD4+T cells have in Multiple Sclerosis, the CD8+ T cells involvement in the pathology is still in its early phases of investigation. Proteasome degradation is the key step in the production of MHC class I-restricted epitopes and therefore its activity could be an important element in the activation and regulation of autoreactive CD8+ T cells in Multiple Sclerosis. Methodology/Principal Findings Immunoproteasomes and PA28-αβ regulator are present in MS affected brain area and accumulated in plaques. They are expressed in cell types supposed to be involved in MS development such as neurons, endothelial cells, oligodendrocytes, macrophages/macroglia and lymphocytes. Furthermore, in a genetic study on 1262 Italian MS cases and 845 controls we observed that HLA-A*02+ female subjects carrying the immunoproteasome LMP2 codon 60HH variant have a reduced risk to develop MS. Accordingly, immunoproteasomes carrying the LMP2 60H allele produce in vitro a lower amount of the HLA-A*0201 restricted immunodominant epitope MBP111–119. Conclusion/Significance The immunoproteasome LMP2 60HH variant reduces the risk to develop MS amongst Italian HLA-A*02+ females. We propose that such an effect is mediated by the altered proteasome-dependent production of a specific MBP epitope presented on the MHC class I. Our observations thereby support the hypothesis of an involvement of immunoproteasome in the MS pathogenesis.

[1]  D. Kuhn,et al.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. , 2009, Blood.

[2]  J. Hong,et al.  Proteasome modulators: essential chemical genetic tools for understanding human diseases. , 2008, Molecular bioSystems.

[3]  D. Mendonça,et al.  Protective role of the HLA–A*02 allele in Portuguese patients with multiple sclerosis , 2009, Multiple sclerosis.

[4]  Manuel A. Friese,et al.  From genes to function: the next challenge to understanding multiple sclerosis , 2009, Nature Reviews Immunology.

[5]  F. Sallusto,et al.  Dendritic cells up‐regulate immunoproteasomes and the proteasome regulator PA28 during maturation , 1999, European journal of immunology.

[6]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[7]  L. Bernardinelli,et al.  Association between Protective and Deleterious HLA Alleles with Multiple Sclerosis in Central East Sardinia , 2009, PloS one.

[8]  P. Kloetzel,et al.  The N-terminal Flanking Region of the TRP2360–368 Melanoma Antigen Determines Proteasome Activator PA28 Requirement for Epitope Liberation* , 2007, Journal of Biological Chemistry.

[9]  C. Franceschi,et al.  Age dependent impact of LMP polymorphisms on TNFα-induced apoptosis in human peripheral blood mononuclear cells , 2002, Experimental Gerontology.

[10]  J. Granados,et al.  Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. , 2004, Human immunology.

[11]  P. Kloetzel,et al.  A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms , 2006, Biological chemistry.

[12]  D. Galimberti,et al.  HLA-class I markers and multiple sclerosis susceptibility in the Italian population , 2009, Genes and Immunity.

[13]  J. Sutcliffe,et al.  Induction of Golli-MBP Expression in CNS Macrophages During Acute LPS-Induced CNS Inflammation and Experimental Autoimmune Encephalomyelitis (EAE) , 2007, TheScientificWorldJournal.

[14]  A. Strosberg,et al.  Anergy induction in encephalitogenic T cells by brain microvessel endothelial cells is inhibited by interleukin‐1 , 1995, European journal of immunology.

[15]  B. Engelhardt,et al.  Immune function of the blood-brain barrier: incomplete presentation of protein (auto-)antigens by rat brain microvascular endothelium in vitro , 1990, The Journal of cell biology.

[16]  R. Liblau,et al.  An antigen-specific pathway for CD8 T cells across the blood-brain barrier , 2007, The Journal of experimental medicine.

[17]  Tilman Grune,et al.  Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains , 2006, Neurobiology of Aging.

[18]  Claudio Franceschi,et al.  Immunoproteasomes and immunosenescence , 2003, Ageing Research Reviews.

[19]  Elke Krüger,et al.  Interferon‐γ, the functional plasticity of the ubiquitin–proteasome system, and MHC class I antigen processing , 2005, Immunological reviews.

[20]  M. Suarez‐Almazor,et al.  LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis. , 2000, The Journal of rheumatology.

[21]  L. Fugger,et al.  Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? , 2005, Brain : a journal of neurology.

[22]  Hermann-Georg Holzhütter,et al.  Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics. , 2008, Journal of molecular biology.

[23]  Silke Meiners,et al.  Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. , 2010, Cardiovascular research.

[24]  J. Goverman,et al.  Crosspresentation by nonhematopoietic and direct presentation by hematopoietic cells induce central tolerance to myelin basic protein , 2008, Proceedings of the National Academy of Sciences.

[25]  Khalid W. Kalim,et al.  A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis , 2009, Nature Medicine.

[26]  T. Illig,et al.  Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype , 2007, Genes and Immunity.

[27]  Jan Hillert,et al.  HLA-A Confers an HLA-DRB1 Independent Influence on the Risk of Multiple Sclerosis , 2007, PloS one.

[28]  V. Rivera,et al.  Increased CD8+ Cytotoxic T Cell Responses to Myelin Basic Protein in Multiple Sclerosis1 , 2004, The Journal of Immunology.

[29]  J. Antel,et al.  MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. , 1998, Journal of immunology.

[30]  Marcus Groettrup,et al.  Incorporation of major histocompatibility complex – encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon‐γ , 1995, European journal of immunology.

[31]  D. Galimberti,et al.  A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy , 2008, Genes and Immunity.

[32]  H. Wiendl,et al.  Recent clinical trials and future therapies , 2008, Journal of Neurology.

[33]  I. Moldovan,et al.  Multiple sclerosis patients show sexual dimorphism in cytokine responses to myelin antigens , 2008, Journal of Neuroimmunology.

[34]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.

[35]  P. Kloetzel,et al.  Biochemical analysis of proteasomes from mouse microglia: Induction of immunoproteasomes by interferon‐γ and lipopolysaccharide , 2000, Glia.

[36]  L. Fugger,et al.  Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis , 2008, Nature Network Boston.

[37]  N. Risch,et al.  A comparison of linkage disequilibrium measures for fine-scale mapping. , 1995, Genomics.

[38]  M. Feldman,et al.  A general asymptotic property of two-locus selection models. , 1988, Theoretical population biology.

[39]  Stella Elkabes,et al.  Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. , 2007, Journal of proteome research.

[40]  Isidro Ferrer,et al.  Neuronal Induction of the Immunoproteasome in Huntington's Disease , 2003, The Journal of Neuroscience.

[41]  Peter R Jungblut,et al.  Intermediate-type 20 S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation. , 2007, Journal of molecular biology.

[42]  Gavin Giovannoni,et al.  Multiple sclerosis: the environment and causation , 2007, Current opinion in neurology.

[43]  S. Vukusic,et al.  Steroid hormones in multiple sclerosis , 2005, Journal of the Neurological Sciences.

[44]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[45]  D. Willoughby,et al.  Presentation of myelin basic protein by normal guinea-pig brain endothelial cells and its relevance to experimental allergic encephalomyelitis. , 1989, Immunology.

[46]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by Melan-A/Mart-1 immunodominant peptide analogs , 1997 .

[47]  R. Rudick,et al.  Effects of sex hormones on costimulatory molecule expression in multiple sclerosis , 2005, Journal of Neuroimmunology.

[48]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[49]  J. Goverman,et al.  CD8+ T cells maintain tolerance to myelin basic protein by 'epitope theft' , 2004, Nature Immunology.